https://biotechmorning.com/news/helus-pharma-ceo-exit-two-months Biotech Morning en 2026-04-24T14:09:50.103Z Two Months and Out: The CEO Exit That Has Biotech Investors Nervous https://biotechmorning.com/news/regeneron-first-gene-therapy-approval-hearing-loss Biotech Morning en 2026-04-24T14:09:08.109Z Regeneron Just Cured a Type of Deafness With a Single Surgery https://biotechmorning.com/news/pfizer-cancer-campaign-fernando-mendoza Biotech Morning en 2026-04-24T14:08:26.720Z Why Pfizer Just Bet Its Cancer Brand on a Rookie Quarterback https://biotechmorning.com/news/avalyn-pharma-ipo-inhaled-lung-drugs Biotech Morning en 2026-04-24T14:07:43.525Z The $200M Bet That You've Been Taking Your Lung Drugs Wrong https://biotechmorning.com/news/regeneron-last-holdout-white-house-drug-pricing-deal Biotech Morning en 2026-04-24T14:06:57.128Z Regeneron Was the Last Holdout. The White House Just Got Its Deal. https://biotechmorning.com/news/lilly-ghosted-rigel-ripk1-deal Biotech Morning en 2026-04-23T14:13:18.405Z Lilly Just Ghosted a $960 Million Drug Deal https://biotechmorning.com/news/merck-billion-dollar-google-cloud-ai-deal Biotech Morning en 2026-04-23T14:12:32.008Z Merck Just Bet $1 Billion That Google Can Fix Drug Development https://biotechmorning.com/news/daraxonrasib-pancreatic-cancer-first-line-results Biotech Morning en 2026-04-23T14:11:49.120Z The Drug That Might Rewrite Pancreatic Cancer's Brutal Math https://biotechmorning.com/news/137m-bet-cancer-smart-bombs-sidewinder Biotech Morning en 2026-04-23T14:11:08.868Z The $137M Bet on Cancer's Smart Bombs https://biotechmorning.com/news/gene-therapy-deaf-hear-whispers Biotech Morning en 2026-04-23T14:10:26.881Z The Gene Therapy That's Making Deaf People Hear Whispers https://biotechmorning.com/news/novartis-abelacimab-anticoagulant-retreat Biotech Morning en 2026-04-23T14:09:48.037Z Novartis Just Spent $925M on a Drug That Can't Beat the Reigning Champ https://biotechmorning.com/news/lilly-300m-crossbridge-bio-dual-payload-adc Biotech Morning en 2026-04-23T14:09:04.056Z Lilly's $300M Bet on a Biotech That Doesn't Even Have a Drug in Humans Yet